Botanix Raises A$14.9m in First Tranche of A$40m Placement

Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an update.

Botanix Pharmaceuticals has completed tranche one of a planned A$40 million equity placement, raising approximately A$14.9 million before costs through the issue of nearly 248 million new shares at A$0.06 each to institutional and sophisticated investors. The remaining funds are to be raised subject to shareholder approval at a general meeting expected in early April 2026, and the newly issued shares can trade immediately under applicable Australian securities law exemptions.

The capital raising strengthens Botanix’s balance sheet as it advances its dermatology portfolio following FDA approval of Sofdra for primary axillary hyperhidrosis, positioning the company to capitalise on its first-in-class therapy in a niche but underserved market. The immediate tradeability of the new shares may enhance liquidity for existing and new investors, while shareholder approval for the second tranche remains a key step for the full funding package.

The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

More about Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited is a dermatology company listed on the ASX and based in Philadelphia and Phoenix in the U.S. The company has received FDA approval for its lead product Sofdra, the first and only new chemical entity approved to treat primary axillary hyperhidrosis, targeting patients with limited options for this socially challenging condition.

Average Trading Volume: 7,116,835

Technical Sentiment Signal: Sell

Current Market Cap: A$124.1M

See more data about BOT stock on TipRanks’ Stock Analysis page.